Oral administration of a retinoic acid receptor antagonist reversibly inhibits spermatogenesis in mice

Sanny S W Chung, Xiangyuan Wang, Shelby S. Roberts, Stephen M Griffey, Peter R. Reczek, Debra J. Wolgemuth

Research output: Contribution to journalArticle

59 Scopus citations

Abstract

Here we investigated a pharmacological approach to inhibit spermatogenesis in the mouse model by manipulating retinoid signaling using low doses of the pan-retinoic acid receptor (RAR) antagonist BMS-189453. Spermatogenesis was disrupted, with a failure of spermatid alignment and sperm release and loss of germ cells into lumen, abnormalities that resembled those in vitamin A-deficient and RARα-knockout testes. Importantly, the induced sterility was reversible. Enhanced efficacy and a lengthened infertility period with full recovery of spermatogenesis were observed using systematically modified dosing regimens. Hematology, serum chemistry, and hormonal and pathological evaluations revealed no detectable abnormalities or adverse side effects except the distinct testicular pathology. Our results suggest that testes are exquisitely sensitive to disruption of retinoid signaling and that RAR antagonists may represent new lead molecules in developing nonsteroidal male contraceptives.

Original languageEnglish (US)
Pages (from-to)2492-2502
Number of pages11
JournalEndocrinology
Volume152
Issue number6
DOIs
StatePublished - Jun 2011

ASJC Scopus subject areas

  • Endocrinology

Fingerprint Dive into the research topics of 'Oral administration of a retinoic acid receptor antagonist reversibly inhibits spermatogenesis in mice'. Together they form a unique fingerprint.

  • Cite this